Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.

Author: Maur Fautilar
Country: Libya
Language: English (Spanish)
Genre: Love
Published (Last): 28 December 2004
Pages: 160
PDF File Size: 12.22 Mb
ePub File Size: 12.85 Mb
ISBN: 418-3-66894-118-5
Downloads: 48548
Price: Free* [*Free Regsitration Required]
Uploader: Mezirn

Biologie moléculaire de la leucémie myéloïde chronique : dernières avancées – EM|consulte

The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties. Indian J Hematol Blood Transfus. A retrospective study of leukemia epidemiology in Northern Tunisia.

International recommendations cronique the management of CML and treatment adjustments.

Hematologic and cytogenetic response to Imatinib mesylate in chronic myelogenous leukemia. Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be specified in the future.

Leucémie myéloïde chronique (LMC)

Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: Regional variations in leucemue at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Les inhibiteurs des kinases. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. East Afr Med J. Chronic myeloid leukemia advances lejcemie biology and new approaches to treatment.


You can move this window by clicking on the headline. Molecular biology of bcr-abl1-positive CML. Contact Help Who are we? Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.

Médecine et Santé Tropicales

For the remaining half of patients, the causes leading to the myelode relapse deserve to be further analyzed. Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Access to the PDF text. If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal chroniqu.

N Engl J Med. Clinical trials have validated TKI discontinuation strategies in patients with sustained deep molecular response.

S Af Med J. Access to the full text of this article requires a subscription. Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, ponatinib has led to improved overall and disease-free survival of patients. The persistence of TKI-refractory leukemic stem cells could explain this result.


The Glivec international patient assistance programme: Access to the text HTML. Top of the page – Article Outline. If you are a subscriber, please sign in ‘My Account’ at the top right of the screen. Personal information regarding our website’s visitors, including their identity, is confidential.

Journal page Archives Contents list. Chronic myeloid leukaemia in South African blacks.

Orphanet: LMC France Leucemie Myeloide Chronique France

Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction. You may thus request that mteloide data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. New technologies digital PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods.

Clinical and pronognostic features of Nigerians with chronic myeloid leukemia.

Chronic myeloid leukaemia in central Africans. New strategies to eradicate these residual cells by targeting the hematopoietic niche or directly the leukemic stem cells are being developed.

Outline Masquer le plan. An experience from eastern India.